使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning. My name is Amy, and I will be your conference operator today. At this time, I would like to welcome everyone to Valeant Fourth Quarter and Full Year 2017 Earnings Call. (Operator Instructions)
早安。我叫 Amy,今天將擔任各位的電話會議接線員。此刻,我謹代表公司歡迎各位參加 Valeant 2017 年第四季及全年財報電話會議。(接線員指示)
Art Shannon, SVP of Investor Relations and Global Communications, you may begin your conference.
投資人關係與全球傳播資深副總裁 Art Shannon,您可以開始主持會議。
Arthur J. Shannon - Senior VP and Head of IR & Communications
Arthur J. Shannon - Senior VP and Head of IR & Communications
Thank you, Amy. Good morning, everyone, and welcome to Valeant Pharmaceuticals Fourth Quarter Full Year 2017 Financial Results Conference Call. Participating on today's call are Chairman and Chief Executive Officer Mr. Joe Papa; and Chief Financial Officer, Mr. Paul Herendeen. In addition to this live webcast, a copy of today's slide presentation and a replay of this conference call will be available on our website under the Investor Relations section.
謝謝你,Amy。各位早安,歡迎參加 Valeant Pharmaceuticals 2017 年第四季及全年財務結果電話會議。今天與會者包括董事長兼執行長 Joe Papa 先生,以及財務長 Paul Herendeen 先生。除本次即時網路直播外,今日簡報投影片的副本與本次電話會議的重播,將可於我們網站的投資人關係專區取得。
Before we begin, we'd like to remind that presentation today contains forward-looking information. We would ask that you take a moment to read the forward-looking statement legend at the beginning of our presentation as it contains important information. This presentation contains non-GAAP financial measures. For more information about these measures, please refer to Slide 2 of the presentation. Non-GAAP reconciliations can be found in the appendix of the presented posted on our website.
在開始之前,我們想提醒各位,今天的簡報包含前瞻性資訊。請各位花一點時間閱讀簡報開頭的前瞻性聲明說明,因其包含重要資訊。本簡報包含非 GAAP 財務衡量指標。關於這些衡量指標的更多資訊,請參閱簡報第 2 頁。非 GAAP 對帳表可於我們網站所張貼之簡報附錄中查閱。
Finally, the financial guidance in this presentation is effective as of today only. It is our policy generally to not updated guidance until the following quarter and not to update or affirm guidance other than through broadly disseminated public disclosure.
最後,本簡報中的財務指引僅以今日為準。我們的一般政策是在下一季之前通常不更新指引,且除非透過廣泛發布的公開揭露,否則不更新或確認指引。
With that, it is my pleasure to turn the call over to Joe.
接下來,我很高興把電話會議交給 Joe。
Joseph C. Papa - Chairman of the Board and CEO
Joseph C. Papa - Chairman of the Board and CEO
Thanks, Art. Let's start with the topics for today's call. First, I will run through the fourth quarter and full year highlights and briefly review the key achievements of our businesses. I'll then turn the call over to our CFO, Paul Herendeen, to review about the fourth quarter and full year financial results and provide our guidance for 2018. Finally, I will wrap up with the 2018 catalysts before opening the line for questions.
謝謝你,Art。我們先從今天電話會議的議題開始。首先,我將回顧第四季與全年重點,並簡要說明各業務的關鍵成果。接著我會把電話會議交給我們的財務長 Paul Herendeen,請他回顧第四季與全年財務結果,並提供我們 2018 年的指引。最後,我將以 2018 年的催化劑作結,然後開放提問。
Beginning on Slide 4, approximately 21 months ago, we established a multiyear plan for Valeant's turnaround. After working to stabilize the company, we are now well into the second phase of the plan, the turnaround, where we're taking steps to drive shareholder value. Our 3 main areas of focus are: resolving legacy issues and derisking the balance sheet; investing in core franchises with attractive growth; and launching new products with meaningful opportunities. We've built a world-class organization, and we are confident that we can continue to successfully execute on these initiatives.
從第 4 頁投影片開始,大約在 21 個月前,我們為 Valeant 的轉型制定了一項多年計畫。在致力於穩定公司之後,我們目前已深入進入計畫的第二階段——轉型期——在此階段我們正採取措施以提升股東價值。我們的三大重點領域為:解決歷史遺留問題並降低資產負債表風險;投資於具吸引力成長的核心事業群;以及推出具重大機會的新產品。我們已建立世界級的組織,並有信心能持續成功執行這些倡議。
Moving now to Slide 5. We provide an overview of what we have accomplished in 2017. It's been a very busy and productive year. Bausch + Lomb/International, which represents more than half of our 2017 revenues, grew organically in the mid-single digits during each of the 4 quarters of 2017. Our Salix business is also growing nicely. That business generated mid-single-digit or higher organic revenue growth during the last 3 quarters of 2017.
接著看第 5 頁投影片。我們概述 2017 年已完成的事項。這是一個非常忙碌且成果豐碩的一年。Bausch + Lomb/International 佔我們 2017 年營收的一半以上,在 2017 年四個季度中每一季的有機成長皆達到中個位數百分比。我們的 Salix 業務也成長良好。該業務在 2017 年最後三個季度的有機營收成長達到中個位數百分比或更高。
In addition to growing our core businesses, another important area of focus throughout the year has been advancing our new product pipeline. We launched more than 100 products globally last year, including AQUALOX contact lenses in Japan and Biotrue ONEday lenses for astigmatism in Europe. In the U.S., we launched VYZULTA and SILIQ. We received FDA approval for LUMIFY, FDA acceptance to file for DUOBRII and the clearance of next generation of Thermage System. At the same time, we've continued to make progress in our efforts to strengthen the balance sheet. As of today, we have reduced total debt by more than $6.7 billion since the end of the first quarter of 2016.
除了推動核心業務成長之外,全年另一個重要的重點領域是推進我們的新產品研發管線。去年我們在全球推出超過 100 項產品,包括在日本推出 AQUALOX 隱形眼鏡,以及在歐洲推出適用於散光的 Biotrue ONEday 鏡片。在美國,我們推出了 VYZULTA 與 SILIQ。我們取得 LUMIFY 的 FDA 核准、DUOBRII 的 FDA 受理申請,以及新一代 Thermage System 的核准放行。同時,我們也持續在強化資產負債表方面取得進展。截至今日,自 2016 年第一季末以來,我們已將總負債降低超過 67 億美元。
Our legal team has done an outstanding job reducing the legal liabilities facing the company. From the beginning of 2017 through today, we achieved dismissals, settlements or other with positive outcomes in more than 80 litigations and investigations all of which related to historical matters. Notably, we agreed to resolve the Allergan securities litigation subject to court approval, which was an important milestone to resolve. We believe that our insurance policies are sufficient to cover the settlement cost and legal fees. In a recent development, we've agreed to resolve the SOLODYN antitrust litigation, with the class settlement amounting to $258 million (sic) [$58 million] and which will be remaining those subject to court approval. Also, we simplified the supply chain by reducing number of manufacturing sites we operate by 23%. And we're in the process of discontinuing more than 1,900 SKUs. These changes have resulted in cost improvements of approximately $90 million in 2017 alone. Delivering on our commitments have been and continues to be a major focus of the team.
我們的法務團隊在降低公司面臨的法律責任方面表現出色。自 2017 年初至今,我們在 80 多起訴訟與調查中取得撤訴、和解或其他正面結果,且皆與歷史事項相關。值得注意的是,我們已同意在法院核准的前提下解決 Allergan 證券訴訟,這是重要的解決里程碑。我們相信,我們的保險保單足以涵蓋和解成本與法律費用。在近期進展方面,我們已同意解決 SOLODYN 反托拉斯訴訟,集體和解金額為 2.58 億美元(原文如此)[$5,800 萬美元],且仍須經法院核准。此外,我們透過將營運中的製造據點數量減少 23% 來簡化供應鏈。我們也正在逐步停產超過 1,900 個 SKU。僅在 2017 年,這些變革就帶來約 9,000 萬美元的成本改善。兌現我們的承諾一直是、並將持續是團隊的主要重點。
Moving now to Slide 6. First, I want to call out the 4 sequential quarters of mid-single-digit organic revenue growth in the segment. As you could see from the chart on the right, this sustained growth follows a declining to relatively flat period in the prior year. These results were led by strong sales in Global Consumer, Global Vision Care and our International business. I also want to highlight the growing e-commerce presence of the Global Consumer and Vision Care business. On Amazon, B + L grew by 58% in 2017 compared to 2016. And given the strength of the B + L brand in China, we're excited to see that Alibaba sales spiked about 35% on Single's Day, which is a quarter 4 Chinese shopping holiday. Finally, after launching VYZULTA at the end of 2017, we're excited that this proven treatment is now available to lower intraocular pressure for patients with glaucoma. The global glaucoma market represents a $6 billion opportunity, and it's expected to grow at compound annual growth rate of 15%, eventually accounting for more than $11 billion in revenue opportunity by the end of 2020.
接著看第 6 頁投影片。首先,我想特別指出該事業部連續 4 個季度的有機營收成長皆達中個位數百分比。如右側圖表所示,這樣的持續成長是在前一年下滑至相對持平的一段期間之後出現的。這些成果主要由全球消費品、全球視力保健以及我們的國際業務強勁銷售所帶動。我也想強調全球消費品與視力保健業務日益成長的電商布局。在 Amazon 上,B + L 於 2017 年相較 2016 年成長 58%。此外,鑑於 B + L 品牌在中國的強勢表現,我們很高興看到在「雙十一」(第四季的中國購物節)期間,Alibaba 的銷售激增約 35%。最後,在 2017 年底推出 VYZULTA 後,我們很高興這項經證實的治療方案如今可用於降低青光眼患者的眼內壓。全球青光眼市場代表著 60 億美元的機會,預期將以 15% 的年複合成長率成長,並在 2020 年底前最終帶來超過 110 億美元的營收機會。
As an update, we also recently learned that Express Scripts has agreed to begin coverage of VYZULTA under an unrestricted access position among the commercial ESI national preferred and basic formularies. This will give us access to an additional 23 million people in the U.S.
最新進展方面,我們也在近期得知 Express Scripts 已同意開始在商業 ESI 全國優選與基本處方集(formularies)中,以不受限制的給付地位納入 VYZULTA。這將使我們在美國額外觸及 2,300 萬人。
On to Slide 7 for the update on Salix business, which grew organically 5% in 2017 and 5% in the quarter year-over-year. XIFAXAN is performing well delivering organic revenue growth of 5% in 2017. We have very good momentum behind XIFAXAN, both in IBS-D and hepatic encephalopathy, and we believe we have a durable product in XIFAXAN, which we're continuing to invest in through the study of new indications and new formulations. XIFAXAN TRx unit volume growth was up 4% in Q4 2017 compared to 2016, driven by the Primary Care expansion and sales force messaging on the proper dosing for IBS-D. As you can see from the chart in the upper-right corner, since we added a Primary Care (inaudible) February 2017, TRx' are up approximately 10%. This trend has continued in the first quarter as we're up another 7.3% for January 2018. And finally, over the trailing 12 months, XIFAXAN achieved blockbuster status of $1 billion of sales as of January 2018. And I want to congratulate the entire Salix's team on that achievement.
接著看第 7 張投影片,更新 Salix 業務,其在 2017 年有機成長 5%,本季亦較去年同期有機成長 5%。XIFAXAN 表現良好,2017 年帶來 5% 的有機營收成長。XIFAXAN 在 IBS-D 與肝性腦病變兩個領域皆具備非常好的動能;我們相信 XIFAXAN 是一項具持久性的產品,並將持續透過新適應症與新劑型研究加碼投資。XIFAXAN 的 TRx 處方量在 2017 年第四季較 2016 年成長 4%,主要受初級照護(Primary Care)擴張,以及業務團隊針對 IBS-D 正確劑量的訊息傳遞所帶動。如右上角圖表所示,自我們於 2017 年 2 月新增初級照護(聽不清)後,TRx 約上升 10%。此趨勢在第一季仍持續,2018 年 1 月我們再成長 7.3%。最後,在過去 12 個月期間,截至 2018 年 1 月,XIFAXAN 銷售額達 10 億美元,成為重磅產品(blockbuster)。我也要恭喜整個 Salix 團隊達成這項成就。
RELISTOR is also performing well. Weekly TRx growth for RELISTOR increased approximately 40% in 2017 as we show in the chart on the lower-right corner.
RELISTOR 的表現也很不錯。如右下角圖表所示,RELISTOR 的每週 TRx 成長在 2017 年約增加 40%。
Overall, we are making good progress in our GI business, and we look forward to continuing to build this franchise for the future.
整體而言,我們在腸胃(GI)業務方面進展良好,並期待持續打造此一事業平台,以因應未來。
Turning to Slide 8, Ortho Dermalogics. We remain focused on returning our dermatology business to growth, and we have a clear path for achieving that goal by investing in new product approvals and launches, global expansion and business synergies. Looking at the milestones we called out in the top right corner, you can see we have core group of 5 recently launched or soon-to-be approved products that represent a meaningful growth opportunity for our dermatology business. With SILIQ and the potential approvals for DUOBRII, JEMDEL, we expect they're a very important group of product that could help improve the lives of patients with psoriasis. And when you add Retin-A Micro in the late-stage acne treatment, ALTRENO, to the group, you can see how these products collectively represent an opportunity to restore this business to grow in the coming years.
接著看第 8 張投影片:Ortho Dermalogics。我們仍專注於讓皮膚科業務重回成長軌道;透過投資新產品核准與上市、全球擴張以及業務協同效益,我們有一條清晰的達標路徑。從右上角我們提到的里程碑可見,我們有一個核心產品組合,共 5 項近期已上市或即將獲准的產品,為皮膚科業務帶來具意義的成長機會。隨著 SILIQ,以及 DUOBRII、JEMDEL 的潛在核准,我們預期這是一組非常重要的產品,可望幫助改善乾癬患者的生活。此外,若再把用於晚期痤瘡治療的 Retin-A Micro 與 ALTRENO 納入,你會看到這些產品合計代表未來幾年讓此業務恢復成長的機會。
If you take a look at the chart at the bottom right, you'll see how these new products in high-growth markets add to our base business and the growth trajectory we are anticipating. A return to modest growth in 2019 and ramp up from there. We also increased the derm sales force by more than 25% last month to support this growth.
若你看右下角的圖表,會看到這些位於高成長市場的新產品如何在既有基礎業務之上,推動我們所預期的成長軌跡。2019 年回到溫和成長,並自此逐步加速。我們也在上個月將皮膚科業務團隊擴編超過 25%,以支援這項成長。
I'll talk more about our plans to double Ortho Dermatologics business after Paul takes us through the financial results and 2018 guidance. But let me spend a minute here on SILIQ, which we launched in July of 2017. We expected SILIQ would have a slow initial uptake based on the labeling, but believe it will represent an important long-term opportunity. Early market access for SILIQ was better than expected. At less than 6 months, we have covered for more than 50% of commercial life and expect to soon reach above 70%. And we are continuing to expand by targeting broader audience of high-volume prescribers of injectable biologics. To date, we have REMS certified approximately 100,000 -- 1,542 physicians or about 70% of the key prescribers in this broad injectable biologicals. Importantly, 90% of patients who have started using SILIQ have stayed on therapy, which is an important outcome. In addition, new data suggest that SILIQ reduces the burden from anxiety and depression in people with psoriasis.
在 Paul 帶我們看完財務結果與 2018 年指引後,我會再多談我們將 Ortho Dermatologics 業務規模倍增的計畫。不過先花一點時間談 SILIQ,我們在 2017 年 7 月推出。基於標籤(labeling)限制,我們原本預期 SILIQ 初期採用會較慢,但相信它將帶來重要的長期機會。SILIQ 的早期市場准入(market access)優於預期。在不到 6 個月內,我們已涵蓋超過 50% 的商業保險人群,並預期很快可達到 70% 以上。我們也持續透過鎖定更廣泛的高處方量注射型生物製劑開立者來擴張。截至目前,我們已完成 REMS 認證約 100,000 -- 1,542 位醫師,約占此廣泛注射型生物製劑關鍵處方醫師的 70%。重要的是,開始使用 SILIQ 的患者中有 90% 持續接受治療,這是一個重要成果。此外,新數據顯示 SILIQ 可降低乾癬患者的焦慮與憂鬱負擔。
On Slide 9. Before I turn it over to Paul, I want to call one important takeaway. The Bausch + Lomb/International segment and the Salix business, which represent approximately 3/4 of our revenue, grew organically in the mid-single digits in 2017. We see this clear evidence that the investments we are making in our core business are delivering results.
第 9 張投影片。在交棒給 Paul 之前,我想強調一個重要重點。Bausch + Lomb/International 事業部與 Salix 業務合計約占我們營收的 3/4,兩者在 2017 年皆以中個位數(mid-single digits)的幅度實現有機成長。我們清楚看到證據顯示,我們對核心業務所做的投資正在產生成果。
Paul, I'll turn it over to you
Paul,接下來交給你。
Paul S. Herendeen - EVP of Finance & CFO
Paul S. Herendeen - EVP of Finance & CFO
Thanks, Joe. Before I start, when we talk about organic growth, I just want to make sure everyone understands that means on a constant-currency basis and adjusted to remove the impact of the businesses that we divested.
謝謝,Joe。在我開始之前,談到有機成長時,我想先確保大家理解:這是以固定匯率(constant-currency)為基礎,並調整剔除我們已處分業務的影響。
So here we go. Starting with the quarter on Slide 10 with segment details on Slide 11, 12 and 13. We posted a solid quarter with reported revenue and adjusted EBITDA squarely in line with our expectations. Reported revenues were down 10%. Divested assets accounted for roughly 9 percentage points or $221 million of that reported decline. Further adjusting for FX, so on organic basis, revenue was down 2%. If you peel back the impact of the LOE bucket, our core or go-forward assets actually grew about 1%. The major items driving that growth were the B + L/International segment, which grew 4% organically, and our Salix business, which grew 5% organically. Within the B + L/International segment, all 5 subunits posted organic growth over the prior-year quarter. In order: Global Consumer was the star, up 9%: Global Vision Care up 5%; Global Surgical and International Rx were both up 2%; and Global Ophtho was up 1%. In Salix, XIFAXAN led the way, was up 10%. Ortho Dermalogics was a growth headwind in the quarter down 36%, as the rebasing of that business continues. I'll spend a second.
那我們開始。先從第 10 張投影片的本季表現談起,分部細節在第 11、12 與 13 張投影片。我們交出一個穩健的季度,公告營收與調整後 EBITDA 均與我們的預期一致。公告營收下滑 10%。已處分資產約占該下滑的 9 個百分點,或 2.21 億美元。再進一步調整匯率影響後,也就是以有機口徑來看,營收下滑 2%。若剔除 LOE(專利到期)組合的影響,我們的核心/未來持續經營資產實際上約成長 1%。帶動該成長的主要項目為 B + L/International 事業部(有機成長 4%)以及 Salix 業務(有機成長 5%)。在 B + L/International 事業部內,5 個子單位相較去年同期皆呈現有機成長。依序為:全球消費品(Global Consumer)表現最亮眼,成長 9%;全球視力保健(Global Vision Care)成長 5%;全球手術(Global Surgical)與國際處方藥(International Rx)皆成長 2%;全球眼科(Global Ophtho)成長 1%。在 Salix,XIFAXAN 表現領先,成長 10%。Ortho Dermalogics 在本季對成長形成逆風,下滑 36%,因該業務的基期重置仍在持續。我稍微補充一下。
Our ASPs in derm have stabilized and now units are stabilizing as well. Not compared with the prior year, but looking at time series Rx data as a proxy for the units, you can see the flattening out. The dermatology market has undergone significant changes during the last 2 years. Third-party payers have dramatically reduced patient access to products like those that comprise our legacy derm portfolio. That has had an impact on both net realized prices and on unit volumes. Our legacy products continue to bring value to patients, just at lower volumes and lower net realized prices than in the past. As we move forward from here, we intend to grow our presence in dermatology through innovation. And that means, the development and launch of new products like SILIQ and RAM 0.06% and late-stage development drugs like DUOBRII, like JEMDEL and like ALTRENO that represent beneficial options for physicians and their patients, and therefore, we expect will be more broadly available to patients.
我們皮膚科業務的 ASP(平均銷售價格)已趨於穩定,現在銷量也開始穩定。雖然與去年同期相比仍未恢復,但若以時間序列的 Rx 處方數據作為銷量的替代指標,你可以看到趨勢正在走平。皮膚科市場在過去兩年經歷了重大變化。第三方支付方大幅降低患者對我們傳統皮膚科產品組合中這類產品的可及性。這同時影響了淨實現價格與銷量。我們的傳統產品仍持續為患者帶來價值,只是相較過去,銷量更低、淨實現價格也更低。展望未來,我們打算透過創新來擴大在皮膚科領域的布局。這意味著開發並推出像 SILIQ 與 RAM 0.06% 這樣的新產品,以及像 DUOBRII、JEMDEL、ALTRENO 這些處於後期開發階段的藥物;它們能為醫師及其患者提供有益的治療選項,因此我們預期患者將能更廣泛地取得。
The other revenue decline during the quarter was predictably the U.S. Diversified Products segment, where the majority of the impact of the LOE bucket is felt. Organically, the segment was down 12%, but the LOE bucket drove 14 percentage points of decline, while the balance of the Diversified segment actually grew 2%. Gross margin in the quarter was down over 200 basis points versus the prior-year quarter. The main driver was reduced gross margins in the B + L/International segment, where margin just climbed by some 260 basis points due in part to the transactional impact of unfavorable movements in FX. Gross margin in that Diversified segment also declined roughly 195 basis points driven by mix as revenues from the high-margin LOE products declined. Gross margin in the Branded Rx segment was up roughly 195 basis points due to the impact of that Dendreon divestiture.
本季其他營收下滑如預期地出現在美國多元化產品(U.S. Diversified Products)事業部,因為 LOE 組合的影響主要在此反映。以有機口徑計算,該事業部下滑 12%,但 LOE 組合帶來了 14 個百分點的下滑,而多元化事業部其餘部分實際上成長了 2%。本季毛利率較去年同期下滑超過 200 個基點。主要驅動因素是 B + L/國際(B + L/International)事業部毛利率下降,其中毛利率僅上升約 260 個基點,部分原因是外匯不利變動所造成的交易性影響。該多元化事業部的毛利率亦約下滑 195 個基點,主要由於產品組合影響,因高毛利 LOE 產品的營收下滑。品牌處方藥(Branded Rx)事業部毛利率約上升 195 個基點,係受 Dendreon 出售(divestiture)影響。
Below the gross profit line, adjusted SG&A expenses were down about $26 million compared with the prior-year quarter, the reductions in all expense categories due to the divestitures that took place during the year. Offsetting some, but not all of those reductions was increased promotional spending, particularly within the U.S. Consumer and the U.S. contact lens businesses. You may have seen our TV ads for PreserVision, Ocuvite and Soothe XP. Validating the perspicacity of those investments, the U.S. Consumer and U.S. Vision Care businesses were both up 16% organically compared with Q4 of '16 on very strong volume increases.
在毛利以下,調整後的銷售、一般及行政(SG&A)費用較去年同期減少約 2,600 萬美元;由於年內進行的資產出售,各費用類別均有所下降。部分但未完全抵銷上述降幅的是促銷支出增加,尤其是在美國消費者(U.S. Consumer)與美國隱形眼鏡業務。您可能看過我們為 PreserVision、Ocuvite 與 Soothe XP 投放的電視廣告。這些投資的成效也印證了其前瞻性:相較於 2016 年第四季,美國消費者與美國視力照護(U.S. Vision Care)業務的有機成長率皆為 16%,主要受非常強勁的銷量成長帶動。
Our investment in R&D in the quarter compared with the prior year was down 3%. As I said in the last call, we intend to increase our investment in R&D in the coming years, and when we get to guidance, you'll see that we expect to invest roughly $425 million in R&D in 2018. The net of all that I outlined for the quarter was that adjusted EBITDA on a reported basis was down 19% compared with the prior year quarter. Divested assets and the LOE products accounted for almost 18 percentage points of that decline. So adjusted EBITDA for our remaining base business was down slightly, less than 1% as growth in our B + L/International segment and Salix business was offset mainly by the decline in dermatology. Adjusted EBITDA in the quarter was $875 million.
本季研發(R&D)投資較去年同期下降 3%。如我在上次電話會議所說,我們計畫在未來幾年提高研發投資;在談到財測指引時,您會看到我們預期 2018 年研發投入約 4.25 億美元。綜合我對本季所概述的各項因素,按申報口徑計算的調整後 EBITDA 較去年同期下降 19%。已出售資產與 LOE 產品合計貢獻了該降幅中的近 18 個百分點。因此,我們剩餘的基礎業務之調整後 EBITDA 僅小幅下降、不到 1%;B + L/國際事業部與 Salix 業務的成長,主要被皮膚科業務的下滑所抵銷。本季調整後 EBITDA 為 8.75 億美元。
Moving right along to the full year shown on Slide 14, with additional segment details on Slides 15, 16 and 17. Many of the themes I called out for the quarter apply to the full year as well. Reported revenues were down 2% compared with 2016 with divested assets accounting for roughly 4 percentage points or roughly $387 million of that decline. Unfavorable movements in FX accounted for another minus 1% and the LOE bucket roughly 5 percentage points of decline. Our underlying core businesses were essentially flat compared with the prior year as -- and I think you can see, as we put the contraction of our dermatology business behind us, you can start to see the future growth potential of our core assets. Of our core businesses, the B + L/International segment posted 6% organic growth over 2016. Four of the 5 subunits grew led by the International Rx group up 13% organically benefiting from improved net pricing, and increased volume, mainly due to the inventory drawdown in Poland and Russia in 2016. Global Consumer was up 6% organically, consistent of both -- across both the U.S. and international markets. Global Vision Care was up 3%, also consistent across both the U.S. and international markets. Global Surgical was slightly positive. And Global Ophtho Rx declined a small amount, roughly 20 basis points.
接著看投影片 14 所示的全年表現,更多分部細節請見投影片 15、16 與 17。我在本季提到的許多主題同樣適用於全年。申報營收較 2016 年下降 2%,其中已出售資產約占該降幅的 4 個百分點,約 3.87 億美元。外匯不利變動另造成約 -1%,而 LOE 組合約造成 5 個百分點的下滑。我們的核心基礎業務相較去年基本持平;我想您也看得出來,隨著我們將皮膚科業務的收縮期拋諸腦後,核心資產的未來成長潛力開始顯現。在核心業務中,B + L/國際事業部相較 2016 年有機成長 6%。五個子單位中有四個成長,其中以國際處方藥(International Rx)團隊領先,有機成長 13%,受惠於淨售價改善與銷量增加,主要因 2016 年波蘭與俄羅斯的庫存去化(inventory drawdown)。全球消費者(Global Consumer)有機成長 6%,美國與國際市場皆一致。全球視力照護(Global Vision Care)成長 3%,同樣在美國與國際市場表現一致。全球手術(Global Surgical)略為正成長。全球眼科處方藥(Global Ophtho Rx)小幅下滑,約 20 個基點。
2017 was a good solid year for the B + L/International segment. Revenue in the Branded Rx segment was down 6% organically. Salix finished up 5% organically led by XIFAXAN, which was up 5% even after absorbing roughly $25 million of pipeline inventory reductions over the course of 2017. RELISTOR was up 4%, APRISO up 2%, and we had better-than-expected contribution from Glumetza through the third quarter of the year. LOE shaved some 160 basis points of organic growth off of Salix' result and that's mainly Zegerid. It was a good solid year for Salix after a slow start in Q1.
2017 年對 B + L/國際事業部而言是穩健扎實的一年。品牌處方藥(Branded Rx)事業部營收以有機口徑計算下滑 6%。Salix 以有機口徑計算成長 5%,主要由 XIFAXAN 帶動;即使在 2017 年期間吸收了約 2,500 萬美元的管線庫存減少(pipeline inventory reductions),XIFAXAN 仍成長 5%。RELISTOR 成長 4%,APRISO 成長 2%,且 Glumetza 在第三季前的貢獻優於預期。LOE 使 Salix 的有機成長率減少約 160 個基點,主要來自 Zegerid。在第一季起步較慢之後,Salix 仍交出穩健扎實的一年。
Dermatology is the same story as in the fourth quarter. One factoid for you. Compared with 2016, our net realized pricing declined by only 100 basis points for the full year. We believe the dramatic decline in realized net pricing that we saw in our dermatology business in 2016 are behind us. The Diversified segment declined organically 27%, with 22 points of that decline related to the LOE assets. So the other assets in the segment accounted for roughly 5% of the decline for the full year. As we put the impact of that big bolus of LOE assets behind us in 2018, the balance of the Diversified segment is expected to be a low-single -- excuse me, low- to mid-single-digit decliner off of a much smaller base.
皮膚科的情況與第四季相同。提供一個小數據。相較 2016 年,我們全年實現的淨售價(net realized pricing)僅下降 100 個基點。我們認為 2016 年在皮膚科業務中看到的實現淨售價大幅下滑已成過去。多元化事業部以有機口徑計算下滑 27%,其中 22 個百分點的下滑與 LOE 資產相關。因此,該事業部內其他資產全年約占 5% 的下滑。隨著我們在 2018 年把那一大波 LOE 資產的影響拋在身後,多元化事業部其餘部分預期將在更小的基礎上呈現低個位數——抱歉,是低到中個位數的下滑。
Gross margin for the company decreased by some 280 basis points compared with '16, with the mix of revenues between segments accounting for roughly 120 basis points of that decline. Another driver of the decline in gross margins was the impact of transactional FX losses in part to the B + L/International segment that decreased our margins. The balance was mainly due to the change in product mix within the diversified segment driven by the decline in revenue from the LOE products.
公司全年毛利率較 2016 年下降約 280 個基點,其中各事業部之間的營收組合變化約占 120 個基點的降幅。毛利率下滑的另一項驅動因素,是部分來自 B + L/國際事業部的交易性外匯損失影響,進而壓低我們的毛利率。其餘部分主要源於多元化事業部內產品組合的變化,係由 LOE 產品營收下滑所致。
SG&A expenses for the full year were favorable to '16 by $160 million. Roughly half of the reductions in SG&A were costs that were eliminated in conjunction with the divestitures. Excluding the impact of divestitures, we reduced SG&A expenses relative to '16 by some $31 million across the Branded Rx segment and by roughly $70 million within corporate G&A. And within G&A, $55 million of that was a reduction in share-based comp. Adjusted for divestitures, we actually increased SG&A spending in the B + L/International segment, mainly increased selling expenses in Vision Care and Optho Rx. Investment in R&D for the full year was down 11% as we're not able to immediately redeploy funding from programs eliminated in conjunction with the divestitures.
全年 SG&A 費用較 2016 年改善 1.6 億美元。SG&A 降幅約有一半是配合資產出售而被消除的成本。若排除資產出售的影響,我們相較 2016 年在品牌處方藥(Branded Rx)事業部將 SG&A 費用降低約 3,100 萬美元,並在公司一般及行政(corporate G&A)降低約 7,000 萬美元。而在 G&A 中,其中 5,500 萬美元來自股份基礎薪酬(share-based comp)的減少。在排除資產出售影響後,我們實際上在 B + L/國際事業部增加了 SG&A 支出,主要是視力照護(Vision Care)與眼科處方藥(Optho Rx)的銷售費用增加。全年研發(R&D)投資下降 11%,因為我們無法立即將因配合資產出售而終止之專案所釋出的資金重新配置。
Adjusted EBITDA for the full year was down $737 million. Of the 18% year-over-year decline, roughly 4 percentage points were due to divestitures, roughly 11 percentage points from the impact of the LOE assets, and 1 percentage point from currency. Adjusted EBITDA for the remaining core businesses were essentially flat versus the prior year. Full year adjusted EBITDA was $3.638 billion.
全年調整後 EBITDA 下降了 7.37 億美元。在年對年 18% 的下滑中,約 4 個百分點來自資產剝離,約 11 個百分點來自 LOE 資產的影響,另有 1 個百分點來自匯率。其餘核心業務的調整後 EBITDA 與前一年基本持平。全年調整後 EBITDA 為 36.38 億美元。
Moving to Slides 18, 19 and 20. During Q4, we continued our efforts to improve our capital structure. We use the net proceeds from divestitures to reduce debt, we used cash generated from the business to reduce debt, and we completed successful note offerings during the quarter to further address our 2020 debt maturities. Our most significant financing was the $1.5 billion of senior unsecured notes offering in early December. Regaining access to the unsecured debt markets was an important step as we work to ensure that we have the runway to continue the turnaround and transformation of Valeant. Sitting here today, our long-term debt is down to $25.5 billion, and our next maturities are out in 2020. Plenty more work to do, but we made very substantial progress over the course of 2017 and including in the fourth quarter.
接著看第 18、19 與 20 張投影片。在第四季期間,我們持續努力改善資本結構。我們將資產剝離的淨收益用於降低負債,並使用業務產生的現金來減債;同時我們在本季成功完成票據發行,以進一步處理 2020 年到期的債務。我們最重要的融資是在 12 月初發行 15 億美元的優先無擔保票據。重新取得無擔保債務市場的融資管道,是我們確保有足夠時間跑道以持續推動 Valeant 扭轉與轉型的重要一步。截至今天,我們的長期負債已降至 255 億美元,而下一批到期日落在 2020 年。仍有許多工作要做,但我們在 2017 年(包括第四季)期間已取得非常實質的進展。
In order to maintain flexibility, as we continue to manage our cap structure, we do plan to file a universal shelf around the same time as the filing of our 10-K. This is good practice to have a shelf in place, and this should not and does not signal any specific transaction.
為了維持彈性,在我們持續管理資本結構的同時,我們計畫在提交 10-K 的前後差不多時間申報一份通用型貨架式註冊(universal shelf)。預先備妥貨架式註冊屬於良好做法,這不應、也不會代表任何特定交易的訊號。
Cash flow from operations in the quarter was a strong $578 million and totaled $2.29 billion for the full year.
本季營運活動現金流強勁,為 5.78 億美元;全年合計為 22.9 億美元。
Turning to our guidance for 2018 on Slide 21. We're guiding the revenue in the range of $8.1 billion to $8.3 billion and adjusted EBITDA in the range of $3.05 billion to $3.20 billion. We expect that revenue and EBITDA will be the lowest in Q1 as historically this quarter is seasonally impacted and will generally move higher over the balance of the year.
接著看第 21 張投影片中我們對 2018 年的指引。我們預估營收介於 81 億至 83 億美元,調整後 EBITDA 介於 30.5 億至 32.0 億美元。我們預期營收與 EBITDA 在第一季將是全年最低,因為歷史上該季受季節性因素影響,之後通常會在全年其餘期間逐步走高。
We've included a bridge on Slide 22 to show how we think about those ranges relative to our actual results for 2017. Specifically, you need to adjust our 2017 for the assets we divested, next adjust for the changes in FX. Finally, you should consider the impact of the LOE assets, including the class of 2017 LOE bucket that we called out throughout 2017 and a more manageable group of product phasing LOEs in 2018. In addition to the products highlighted on our LOE Slide in 17, our 2018 guidance takes into consideration the prospect for LOEs for APRISO, UCERIS, Acanya, CUPRIMINE and 2 strengths of SOLODYN. A little color on APRISO and UCERIS. We have risk-adjusted our 2018 revenue and profit forecast for these 2 products as there are some probability that one or both could face generic competition in 2018. Accordingly, our guidance anticipates potential LOEs for both. Here a couple of facts to consider. First, there have been no tentative approvals from the FDA for a generic for either drug. Second, we are actively defending the intellectual property protecting these brands. As we learn more about potential competition, we'll keep you posted. Details of both LOE buckets, the class of 2017, the class of 2018 are shown in the appendix in the slide deck.
我們在第 22 張投影片提供了一個銜接表(bridge),說明我們如何看待這些區間相對於 2017 年實際結果的關係。具體而言,你需要先將 2017 年的數字調整為扣除已剝離的資產,接著再調整匯率(FX)的變動。最後,應考量 LOE 資產的影響,包括我們在 2017 年反覆提到的「2017 年 LOE 組合」以及 2018 年較易管理的一組產品分期 LOE。除第 17 張 LOE 投影片中強調的產品外,我們的 2018 年指引亦納入 APRISO、UCERIS、Acanya、CUPRIMINE 以及 SOLODYN 兩種規格可能發生 LOE 的情況。補充一些關於 APRISO 與 UCERIS 的說明。由於其中一項或兩項在 2018 年可能面臨學名藥競爭,我們已對這兩項產品的 2018 年營收與獲利預測進行風險調整。因此,我們的指引已預先反映兩者可能發生的 LOE。這裡有幾個事實可供參考。第一,FDA 目前尚未對任一藥品的學名藥給予暫准核可(tentative approval)。第二,我們正積極捍衛保護這些品牌的智慧財產權。隨著我們對潛在競爭了解更多,我們會持續向各位更新。兩個 LOE 組合(2017 年組合與 2018 年組合)的細節,已在簡報附錄中列示。
So looking at the bridge on Slide 22. Our revenue guidance implies that we expect our business adjusted for the divested assets, that 2018 expected LOE impact and for FX to grow some 3% to 5% and our adjusted EBITDA to be up 1% to 6% relative to our base businesses performance in 2017. Excluding divested assets and the impact of LOEs, our B + L/International segment and our Salix unit are expected to generate solid mid-single-digit revenue growth. Our dermatology business is expected to decline in 2018 versus '17. While the business stabilized in the second half of '17, the first half of 2018 will have a tougher comp for us with the prospect of turning the corner to growth later in the year as our new product launches take hold.
因此,回到第 22 張投影片的銜接表。我們的營收指引意味著:在扣除已剝離資產、納入 2018 年預期 LOE 影響並考量匯率後,我們預期業務將成長約 3% 至 5%;而相較於 2017 年基礎業務表現,調整後 EBITDA 預期將成長 1% 至 6%。若排除已剝離資產與 LOE 的影響,我們的 B + L/International 事業群與 Salix 事業單位預期可帶來穩健的中個位數營收成長。我們的皮膚科業務預期在 2018 年將較 2017 年下滑。雖然該業務在 2017 年下半年已趨於穩定,但 2018 年上半年對我們而言比較基期更具挑戰;隨著新產品上市逐步發酵,我們有望在年內稍晚轉向成長。
Setting aside the expected decline of the LOE assets, we expect that the balance of the Diversified segment will be relatively stable in 2018 versus '17. Note that in our guidance -- note that our guidance for 2018 incorporates increased spending to support the launches of VYZULTA, LUMIFY, SILIQ, DUOBRII, JEMDEL and others and to support the continued growth of our B + L consumer products. As Joe mentioned, after year-end, we increased the size of our derm sales force by more than 25%. And earlier, I mentioned there are TV ads for some of our B + L consumer brands.
撇開預期 LOE 資產的下滑,我們預期多元化(Diversified)事業群其餘部分在 2018 年相較 2017 年將相對穩定。請注意,在我們的指引中——請注意,我們對 2018 年的指引已納入增加支出,以支持 VYZULTA、LUMIFY、SILIQ、DUOBRII、JEMDEL 等產品的上市,以及支持我們 B + L 消費性產品的持續成長。如 Joe 所提,年末之後我們將皮膚科銷售團隊規模提高了超過 25%。此外,我先前也提到,我們部分 B + L 消費品牌已有電視廣告投放。
Finally, we expect to invest more in R&D in 2018 and than in 2017. The point of this story is that our objective is not to maximize adjusted EBITDA in 2018. It's to ensure that we support each of our go-forward businesses with appropriate resources to drive the best long-term outcomes. Note that we are guiding to a roughly 13% effective tax rate on adjusted earnings for 2018. After giving effect of the impact of U.S. tax reform, we continue to enjoy an attractive and sustainable rate on adjusted earnings. As a result, we converted a large proportion of our earnings to cash, a good thing. Overall, our global operational footprint provides us with the flexibility to adapt to changes in tax laws. And as a result, our 2018 guidance for our effective tax rate on adjusted earnings is roughly the same as our actual adjusted tax rate in 2017. Net-net, the impact of U.S. tax reform on 2018 is that we'll pay a bit more in U.S. cash taxes due to tax reform.
最後,我們預期 2018 年在研發(R&D)上的投資將高於 2017 年。這段敘事的重點在於:我們在 2018 年的目標不是把調整後 EBITDA 最大化。而是確保我們以適當資源支持各項未來核心業務,以推動最佳的長期成果。請注意,我們對 2018 年調整後盈餘的有效稅率指引約為 13%。在反映美國稅改影響後,我們在調整後盈餘上仍享有具吸引力且可持續的稅率。因此,我們將相當大比例的盈餘轉化為現金,這是好事。整體而言,我們的全球營運布局使我們能靈活因應稅法變動。因此,我們對 2018 年調整後盈餘有效稅率的指引,約與 2017 年實際調整後稅率相同。總而言之,美國稅改對 2018 年的影響是:由於稅改,我們在美國需支付的現金稅將略為增加。
Now turning to our longer-range outlook for our company on Slide 23. Joe started off with a slide that talks about our progress towards the transformation of Valeant and shows 2017 and 2018 as the turnaround years. 2018 will set the stage for our transformation to begin. Slide 23 is a visual presentation of our expected revenue progression from 2016 through 2021. Before you get your micrometers out to try to infer more than we are actually trying to say on this slide, the information is not to scale and is simply meant to illustrate the ramp and certain components of revenue through 2021, with 2018 being our trough year. This represents the entirety of our business on reported results, including LOEs. Here is the important part. Sitting here today, we expect our reported revenue to grow at a CAGR of between 4% and 6% off of the midpoint of our 2018 guidance through 2021. Further, we expect our reported adjusted EBITDA to grow at a slightly faster CAGR, 5% to 8%. Please note that, in the case of both revenue and adjusted EBITDA CAGRs, we do not expect the growth over the period from 2018 to '21 will occur in a linear fashion. For example, the impact of the class of 2018 LOEs will dampen but not overwhelm revenue growth in 2019 versus 2018. For the avoidance of doubt, we expect reported revenue to grow beginning in 2019 versus 2018, and for growth to accelerate as our new product launches take hold. The crux of the biscuit is that we now have line-of-sight to the return to growth.
現在把焦點轉到第23頁,談談我們公司較長期的展望。Joe 一開始用一張投影片說明我們推動 Valeant 轉型的進展,並將 2017 與 2018 視為扭轉局面的年份。2018 年將為我們開始轉型奠定基礎。第23頁以視覺方式呈現我們預期 2016 至 2021 年的營收走勢。在你拿出游標卡尺、試圖從這張投影片推敲出超出我們實際想表達的內容之前,先說明:此處資訊並非按比例繪製,只是用來示意至 2021 年的爬坡以及營收的若干組成要素,其中 2018 年為我們的谷底年度。這代表我們在已揭露結果下的整體業務,包括 LOE(專利到期)。重點在這裡。以我們目前的觀點,我們預期自 2018 年指引中點起算至 2021 年,已揭露營收將以 4% 至 6% 的年複合成長率(CAGR)成長。此外,我們預期已揭露的調整後 EBITDA 將以略快的 CAGR 成長,約 5% 至 8%。請注意,無論是營收或調整後 EBITDA 的 CAGR,我們不預期 2018 至 2021 年期間的成長會呈線性發生。例如,2018 年那一批 LOE 的影響,將在 2019 年相較 2018 年時抑制、但不致壓過營收成長。為避免疑義,我們預期已揭露營收將自 2019 年起相較 2018 年開始成長,且隨著新產品上市逐步發酵,成長將加速。歸根結底,我們現在已能清楚看見重回成長的路徑。
With that let me turn it back to Joe.
說到這裡,我把時間交回給 Joe。
Joseph C. Papa - Chairman of the Board and CEO
Joseph C. Papa - Chairman of the Board and CEO
Thank you, Paul. Let me now turn to Slide #24. Today, I'm excited to announce the global expansion of our dermatology business, Ortho Dermatologics and our aesthetics business, Solta, as a long-proven model demonstrating the synergies between aesthetics and medical dermatology. We've now reached a point with our 5 new launches in late-stage products in dermatology, including SILIQ, DUOBRII, JEMDEL, RAM 0.06%, ALTRENO, along with our investment cycle in Solta with Thermage, Fraxel and Clear + Brilliant that are all bearing out that we decided to combine our dermatology portfolio. Solta is available in countries all around the world and with a geographic expansion of our U.S. dermatology business combined with our new product growth, this will help us to double this business over the next several years. With differentiated products, we believe dermatology and aesthetics are high-growth therapeutic areas with strong consumer qualities that will prove durable and successful over time, especially as our market share increases in the global field.
謝謝你,Paul。接下來請看第24頁。今天,我很高興宣布我們皮膚科業務 Ortho Dermatologics 與醫美業務 Solta 的全球擴張;這是一個長期被驗證的模式,展現醫美與醫療皮膚科之間的協同效應。我們在皮膚科後期產品方面於近期已達到一個階段,包含 5 項新上市/即將上市的產品:SILIQ、DUOBRII、JEMDEL、RAM 0.06%、ALTRENO;同時,我們在 Solta 的投資週期(Thermage、Fraxel 與 Clear + Brilliant)也都逐步展現成果,證明我們決定整合皮膚科產品組合是正確的。Solta 在全球多國均有銷售;結合我們美國皮膚科業務的地域擴張與新產品成長,將有助於我們在未來幾年把這項業務規模翻倍。憑藉差異化產品,我們相信皮膚科與醫美是高成長的治療領域,具備強勁的消費者屬性,隨著我們在全球市場的市占提升,將能在時間推移中展現持久性並取得成功。
Let's discuss the opportunities for our products. Starting with psoriasis. We estimated the combined market for biologic and non-biologic products to be more than $7 billion per year. We believe acne adds another $2 billion. So this is a large and growing area with an addressable market of over $9 billion per year. In addition, there are 7.5 million patients in the U.S. with psoriasis, the majority of which are treated with a topical either alone or as an adjunct to biologics. Ortho Dermatologics has distinct competitive advantages in this area. For example, based on publicly reported data, we believe approximately 35% of the major products in Phase III are awaiting approval in the U.S. for acne, atopic dermatitis and psoriasis are Ortho Dermatologics assets. We also have an opportunity to leverage the synergies from the aesthetic Solta which we are combining with Ortho Dermatologics. This combination will augment our innovative prescription portfolio with a complement of minimally and non-invasive devices that address a broad range of skin care and treatment needs. Combining a strong aesthetics business with derm Rx is a proven model, and we believe our portfolio offers the best range of products in any derm sales force today. On last quarter's call, we announced a target to double the Ortho Dermatologics business, and based on the strength of our pipeline in dermatology, we believe we can achieve that goal by 2022.
接著談談我們產品的機會。先從乾癬開始。我們估計生物製劑與非生物製劑的合計市場規模每年超過 70 億美元。我們認為痤瘡(青春痘)還能再增加 20 億美元。因此,這是一個龐大且持續成長的領域,每年的可服務市場(TAM)超過 90 億美元。此外,美國約有 750 萬名乾癬患者,其中多數以外用藥治療,或作為生物製劑的輔助用藥。Ortho Dermatologics 在此領域具備明顯的競爭優勢。例如,根據公開資料,我們認為在第三期臨床的主要產品中,約有 35% 正在等待美國核准、用於痤瘡、異位性皮膚炎與乾癬者,屬於 Ortho Dermatologics 的資產。我們也有機會運用我們正與 Ortho Dermatologics 整合的醫美業務 Solta 所帶來的協同效應。此一整合將以一系列微創與非侵入式設備補強我們創新的處方產品組合,涵蓋廣泛的皮膚護理與治療需求。將強勢的醫美業務與皮膚科處方藥(derm Rx)結合,是一個已被驗證的模式;我們相信,就目前任何皮膚科銷售團隊而言,我們的產品組合提供了最完整的產品範圍。在上一季的電話會議中,我們宣布 Ortho Dermatologics 業務要翻倍的目標;基於我們皮膚科研發管線的強勁實力,我們相信可在 2022 年前達成該目標。
The graph on the right shows how we plan to get there, primarily through investments we are making in our sales force, global expansion and new product launches. With respect to the sales force, the first pillar, in January, we increased the number of sales reps in derm by more than 25%, and we created a psoriasis team. We believe we'll soon have a very important group of products that could help improve the lives of the patients with psoriasis and want to be well positioned with a sales force that can promote these products to support our growth. The second pillar, global expansion, is expected to provide strong growth from the existing portfolio, especially in Asia Pacific, Europe and the Middle East. In U.S., we received clearance to start to launch the next-generation Thermage, a skin smoothing system that uses patented radio frequency technology to reduce the appearance of fine lines and wrinkles. Strategic partnerships are also being considered to complement R&D investment. Yesterday, we announced an exclusive license agreement with Kaken Pharmaceuticals to develop and commercialize products containing a new chemical entity KP-470, which is an investigational compound for the treatment of psoriasis. If approved, KP-470 will represent a novel drug with an alternative mechanism of action in the topical treatment of psoriasis.
右側的圖表顯示我們計畫如何達成,主要透過我們在銷售團隊、全球擴張與新產品上市方面的投資。就第一支柱—銷售團隊而言,我們在 1 月將皮膚科業務的業務代表人數增加超過 25%,並成立乾癬團隊。我們相信不久後將擁有一組非常重要的產品,可望改善乾癬患者的生活品質;我們希望以能推廣這些產品的銷售團隊做好布局,以支撐我們的成長。第二支柱—全球擴張,預期將為既有產品組合帶來強勁成長,尤其是在亞太、歐洲與中東。在美國,我們已獲准開始推出新一代 Thermage;這是一套皮膚平滑系統,採用專利射頻技術,以減少細紋與皺紋的外觀。我們也在評估策略夥伴關係,以補強研發投資。昨天,我們宣布與 Kaken Pharmaceuticals 簽訂獨家授權協議,開發並商業化含有新化學實體(NCE)KP-470 的產品;KP-470 是一項用於治療乾癬的研究中化合物。若獲核准,KP-470 將成為一款具新穎作用機轉的藥物,提供乾癬外用治療的替代機制。
Finally, bring innovative new products to market will be the key to successfully executing our plan to double the business in 5 years. We have an opportunity before us that not many companies have, the opportunity to launch 5 new dermatological products in a single year. I'll highlight, one of those products in our late-stage pipeline that we think has potential to be a game-changer, DUOBRII, on the next slide. But before I do that, quickly run through the late-stage pipeline. In addition to SILIQ, which I addressed earlier, we have a new formulation of Retin-A Micro or RAM 0.06% that launched in January. Then we have 3 PDUFA dates coming up: DUOBRII on June 18; ALTRENO on August 27; and JEMDEL on October 5. And more products in development. There are other key pipeline candidates for acne and atopic dermatitis in Phase II and III that we're excited about advancing through the pipeline.
最後,將創新新產品推向市場,將是我們在 5 年內成功把業務規模翻倍的關鍵。我們面前有一個不是很多公司都有的機會:在同一年推出 5 款新的皮膚科產品。我會在下一張投影片重點介紹我們後期研發管線中的其中一項產品 DUOBRII;我們認為它有潛力成為改變遊戲規則的產品。但在此之前,先快速帶過後期研發管線。除了我先前提到的 SILIQ,我們也有 Retin-A Micro 的新配方 RAM 0.06%,已於 1 月上市。接著有 3 個即將到來的 PDUFA 日期:DUOBRII 在 6 月 18 日;ALTRENO 在 8 月 27 日;JEMDEL 在 10 月 5 日。並且還有更多產品正在開發中。此外,針對痤瘡與異位性皮膚炎,還有其他處於第二期與第三期的關鍵研發管線候選產品,我們也很期待推進其研發進程。
Moving now to Slide 25. I want to highlight DUOBRII, formerly known as IDP-118. DUOBRII delivers a high-potency corticosteroid with a retinoid in a that psoriasis patients can use topically. If approved, DUOBRII will be the first and only topical high-potency steroid with a retinoid combination lotion with synergistic effects for adults psoriasis patients. First point I want to highlight here is efficacy. Our unique new formulation uses different strengths of halobatesol and tazarotene than previously available with a single-delivery vehicle. We have developed a proprietary vehicle that provides uniform distribution of the drug substance and enhances the barrier to loss of moisture from the skin. The formulation advantageously allows the simultaneous availability of all drug substances at the skin. This ensures uniform distribution allowing the retinoid and corticosteroid to contact the skin simultaneously, which cannot be achieved by simply layering on 2 products on top of one another. Phase III results demonstrated statistically significant improvement in achieving clear to almost clear scores. The photos on the top right show improvement in scaling over an 8-week period. And the images, as you can see, are really striking.
現在轉到第25張投影片。我想特別強調DUOBRII,先前稱為IDP-118。DUOBRII以外用方式,提供高效價皮質類固醇與一種類維生素A(retinoid)的組合,供乾癬患者局部使用。若獲核准,DUOBRII將成為首個且唯一一款,針對成人乾癬患者、具協同效應的外用高效價類固醇與類維生素A複方乳液。我在此要強調的第一點是療效。我們獨特的新配方,採用與既有產品不同濃度的halobetasol與tazarotene,並以單一傳遞載體(single-delivery vehicle)提供。我們已開發出專有載體,可使藥物成分均勻分布,並強化皮膚屏障以減少水分流失。此配方的優勢在於可讓所有藥物成分同時在皮膚上可用。這可確保均勻分布,使類維生素A與皮質類固醇能同時接觸皮膚;而僅僅將兩種產品一層層疊擦,是無法達成的。第三期結果顯示,在達到「清除至幾乎清除」評分方面有統計上顯著的改善。右上方的照片顯示在8週期間鱗屑改善的情況。而這些影像,如各位所見,確實非常顯著。
This takes us to the second point, the safety profile. Let's move to Slide #26. While psoriasis patients tend to prefer a topical treatment, the issue has always been the use of high-potency corticosteroid is limited to a couple weeks duration because of skin atrophy that usually results. Based on the clinical data, we believe DUOBRII safety profile may allow for a longer than 2 weeks. Here are the results of the long-term safety study, which tracked adverse events in patients using IDP-118 once daily for 8 weeks and then intermittently as needed for up to one year. What we saw is that the percentage of patients who reported adverse events did not change from approximately 8 weeks through 52 weeks. Based on this data, we think DUOBRII could be a novel treatment option for people with moderate to severe plaque psoriasis, and we'll learn a lot more as we approach the June 18 PDUFA date. Beyond safety and efficacy, if approved, DUOBRII may help reduce the cost of treating selected psoriasis patients by more than 75% versus an injectable biologic.
接著談第二點:安全性概況。我們移到第26張投影片。雖然乾癬患者往往偏好外用治療,但一直以來的問題是:高效價皮質類固醇的使用通常因會造成皮膚萎縮而被限制在僅數週。根據臨床資料,我們相信DUOBRII的安全性概況可能允許使用超過2週。以下是長期安全性研究結果:追蹤患者每日一次使用IDP-118達8週,之後按需間歇使用,最長可達一年期間的不良事件。我們看到的是,回報不良事件的患者比例,從約8週到52週並未改變。基於這些資料,我們認為DUOBRII可能成為中重度斑塊型乾癬患者的一種新穎治療選擇;隨著我們接近6月18日的PDUFA日期,我們也將了解更多。除了安全性與療效之外,若獲核准,DUOBRII相較於注射型生物製劑,可能協助將特定乾癬患者的治療成本降低逾75%。
Let's move on to Slide #27. Here are the 7 projects that we expect to generate $1 billion of sales collectively over the next 5 years. They are VYZULTA to reduce intraocular pressure in glaucoma patients; LUMIFY for ocular redness; Si-Hy daily contact lenses; SILIQ, JEMDEL and DUOBRII for -- all for the treatment of psoriasis; and of course RELISTOR. Together these products -- 7 products represent less than $100 million of revenue. We're planning to make a significant investment to market these products over the next 5 years, and as we look to peak sales for these products, we expect they will represent over $1 billion of annual sales on a cumulative basis. This is the focus of our turnaround, investing in innovation, getting products approved and successfully commercializing them.
我們繼續到第27張投影片。以下是我們預期在未來5年合計可創造10億美元銷售額的7個專案。它們包括:用於降低青光眼患者眼內壓的VYZULTA;用於眼紅的LUMIFY;Si-Hy每日拋隱形眼鏡;SILIQ、JEMDEL與DUOBRII——皆用於治療乾癬;當然還有RELISTOR。合計而言,這些產品——這7項產品目前代表的營收不到1億美元。我們計畫在未來5年對這些產品的行銷投入重大投資;當我們展望這些產品的高峰銷售時,預期它們累計將代表每年超過10億美元的年銷售額。這就是我們扭轉局勢的重點:投資創新、推動產品獲批並成功商業化。
And on Slide 28, you can see an overview of our pipeline and the progress we are making in innovation from late phase to submissions to product launches. The increased investment we are making in R&D will help us to move these projects through the pipeline into the market. The fact that we have 4 PDUFA dates and subsequent product launches coming up in the next 8 months, after completing 6 U.S. launches in 2017, you'd use sense of the pace and volume of activity in our late-stage pipeline, which brings us to our 2018 commitments and expected targets on Slide #29.
在第28張投影片,各位可以看到我們研發管線的概覽,以及我們在創新方面從後期開發、送件到產品上市所取得的進展。我們增加的研發投資將協助把這些專案沿著管線推進並導入市場。我們在未來8個月內將迎來4個PDUFA日期及後續產品上市;在2017年完成6項美國上市之後,這能讓各位感受到我們後期管線活動的速度與量能——也因此引出第29張投影片中我們2018年的承諾與預期目標。
We've identified 5 commitments and targets that are going to be the key in helping us drive long-term shareholder returns. Each of these commitments is a continuation of the actions that we have taken successfully in 2017. First, we commit to turnaround the Ortho Dermatologics business with a goal of doubling revenue over the next 5 years. Second, we are targeting over $1 billion of annualized revenue from sales with the significant 7 products for the next 5 years. Next, we'll continue to address the company's debt using cash flows and through opportunistic capital markets transactions. We'll look -- keep looking at how we drive operational efficiency with a goal of reducing our cost of goods by approximately $200 million and taking approximately $100 million out of the working capital over the next 5 years. And finally, we commit to increase R&D spend by more than 15% in 2018.
我們已辨識出5項承諾與目標,這些將是協助我們推動長期股東報酬的關鍵。每一項承諾都是我們在2017年已成功採取行動的延續。第一,我們承諾扭轉Ortho Dermatologics業務,目標是在未來5年將營收翻倍。第二,我們的目標是在未來5年,來自這7項重點產品的銷售年化營收超過10億美元。接著,我們將持續運用現金流並透過把握時機的資本市場交易來處理公司的債務。我們也會——持續檢視如何提升營運效率,目標是在未來5年將銷貨成本降低約2億美元,並將營運資金減少約1億美元。最後,我們承諾在2018年將研發支出提高超過15%。
As I said before, I joined Valeant because I believe I saw an opportunity -- a turnaround opportunity of a lifetime. I'm pleased with the progress we made last year in turning this company around. Our team is focused on delivering on the goals we've outlined for 2018 to lead us into the next phase of our multiyear plan.
如我先前所說,我加入Valeant是因為我相信我看到了——一個千載難逢的扭轉局勢機會。我對我們去年在扭轉這家公司方面所取得的進展感到欣慰。我們的團隊專注於達成我們為2018年所概述的目標,帶領我們進入多年計畫的下一階段。
With that, operator, let's open up the lines for questions.
那麼,接線員,請開放電話線讓大家提問。
Operator
Operator
(Operator Instructions) Your first question comes from the line of Gregg Gilbert with Deutsche Bank.
(接線員指示) 第一個問題來自德意志銀行(Deutsche Bank)的Gregg Gilbert。
Gregory B. Gilbert - MD and Senior Analyst
Gregory B. Gilbert - MD and Senior Analyst
I have a few starting with you Paul. On the tax rate, does the 13% represent a cash rate? And how should we think about the cash rate beyond this year? Secondly, for both your -- perhaps on the heels of your comments about the shelf, your decision to share longer-term growth goals, what's your sense of urgency and your appetite to reduce debt in addition to doing it the old-fashioned way with cash flow? And lastly, for Joe, can you update us on any recent developments on the XIFAXAN case with Teva? If the litigation stay were to be extended beyond April 30, is that something you would discuss soon? Any update on that front would be helpful.
我有幾個問題,先從你開始,Paul。關於稅率,13%代表的是現金稅率(cash rate)嗎?那麼今年之後的現金稅率我們應該如何看待?第二,針對你——也許承接你對shelf(註冊架構/棚架註冊)的評論,以及你決定分享較長期的成長目標,你對於除了以傳統方式用現金流之外,進一步降低負債的急迫性與意願(appetite)如何?最後給Joe,你能否更新一下與Teva之間XIFAXAN案件近期的任何進展?如果訴訟暫停(litigation stay)被延長到4月30日之後,這是你們近期會討論的事情嗎?若能提供這方面的任何更新將很有幫助。
Joseph C. Papa - Chairman of the Board and CEO
Joseph C. Papa - Chairman of the Board and CEO
Okay. Well, why don't you start with the tax rate, and then we'll go to that long-term growth.
好的。那不如你先從稅率開始,然後我們再談長期成長。
Paul S. Herendeen - EVP of Finance & CFO
Paul S. Herendeen - EVP of Finance & CFO
Yes. Sure. Starting with the tax rate, the 13% -- to be taxed actually is a component of the 13%. And I think that when we're passed on our public -- something's going wrong with the phone here.
是的。當然。先談稅率,這13%——實際要繳的稅(to be taxed)其實是13%的一個組成部分。我想當我們在公開——電話這邊好像出了點問題。
(technical difficulty)
(技術性困難)
Yes, We're back. Thank you. So when we were last speaking publicly about the impact of tax reform, our belief was that there would be a marginal increase in our tax rate and specifically called out that we expected that our U.S. cash component of our global tax rate would go up, and that's the way it is playing out. I think you saw -- heard my prepared remarks around the tax rate, we're guiding in 2018 to a 13% rate on our adjusted earnings. So that's a global effective tax rate. So it's a -- the cash component is a part of that. Very importantly, and I did have this in my prepared remarks, we continue to have a very good tax structure, which enables us to convert a large proportion of our earnings to cash, which is a good thing when you're a leveraged company like ours, where we need to generate cash in order to continue to address our debt maturities. The second thing on the shelf, you heard me cover that, I said, you linked it into providing longer-term guidance. Let me first say that, well, providing the longer-term guidance because it is difficult for the market to look at the progression of our company. As Joe says, moving from -- stabilizing the company and getting us back to a growth mode, it's hard for the market at large to be able to see that. So we wanted to provide some information about our expectations about revenue and profit over the 3 years following 2018, because they're important years for us where we get past the stabilization, and we get back to a growth mode with our company. Clearly, looking at the way people model us, we wanted to just help put some balance around what we expect. You can believe it or you can choose not to. But we certainly believe in the CAGRs that we put out for both revenue and profit. With respect to the shelf, if we hadn't had our challenges 1 year or more ago, we'd always had it -- had a shelf in place. And this is -- as I said, this is just a good corporate finance practice. You have it so if we need it, it's readily available. To your question about, do we use or how do you feel about reducing debt other than through cash flow, we've consistently said that all levers need to be considered. But as I said, we're not sitting here today saying it is an urgency to go do something tomorrow.
是的,我們回來了。謝謝。所以,當我們上次公開談到稅改的影響時,我們的看法是我們的稅率會小幅上升,並且特別指出我們預期全球稅率中的美國現金稅負部分會上升,而目前的發展正是如此。我想你們已經看到——也聽到我在準備好的發言中談到稅率,我們對2018年的指引是調整後盈餘適用13%的稅率。所以那是一個全球有效稅率。因此——現金稅負部分是其中的一部分。非常重要的是,而且我在準備好的發言中也提到,我們仍然擁有非常良好的稅務架構,使我們能將相當大比例的盈餘轉換為現金;對像我們這樣有槓桿的公司而言,這是好事,因為我們需要產生現金,才能持續因應我們的到期債務。第二點關於擱置式註冊(shelf),你也聽到我提到,我說你把它連結到提供較長期的指引。我先說,之所以提供較長期的指引,是因為市場很難看清我們公司的發展軌跡。如Joe所說,從——穩定公司並讓我們回到成長模式,整體市場很難看得出來。因此,我們想提供一些資訊,說明2018年之後三年內我們對營收與獲利的預期,因為那幾年對我們很重要:我們會走過穩定期,並讓公司回到成長模式。顯然,從大家對我們的建模方式來看,我們只是想協助在我們的預期上提供一些平衡。你可以相信,也可以選擇不相信。但我們確實相信我們對營收與獲利所提出的年複合成長率(CAGR)。至於擱置式註冊,如果不是在一年前或更早我們遇到挑戰,我們本來一直就會維持——會有一個擱置式註冊在那裡。而這——如我所說,這只是良好的公司財務管理作法。你先把它備好,這樣如果需要,就能隨時使用。至於你問到,除了透過現金流之外,我們是否使用或如何看待以其他方式降低負債,我們一貫的說法是所有槓桿都需要納入考量。但如我所說,我們今天並不是坐在這裡說明天就急著要去做什麼。
Joseph C. Papa - Chairman of the Board and CEO
Joseph C. Papa - Chairman of the Board and CEO
Yes. Maybe I'll just add a little bit to what Paul said. Again, I think Paul is absolutely right. What Paul and the team have done, I think, is an outstanding job in dealing with the debt of our company. What we've done, as you know, as we've turned all the cash that we generate into paying down debt, first and foremost. Number 2, we looked historically at noncore asset divestitures. And we've been able to do -- sell and receive proceeds of $3.8 billion on those noncore asset divestitures. I think as we said publicly from this point forward, we may look at some noncore asset divestitures, but they would simply be opportunistic. We're not out here trying to increase those. So that gives us the -- also the opportunity to take some of the working capital improvements and apply those to debt. And I think those will be the primary areas that I just supplement to what Paul said, because I think he answered it quite well. On the question of XIFAXAN and the situation. Just as a reminder to those that -- to our knowledge, there's only have been 1 filing to date. That was the Actavis Teva filing. Sandoz had a program in place, but by everything we've seen, they discontinued that program. The -- you're correct. There's a 1-year stay through April 30, that's associated with a regulatory stay as well through July 28 of 2019. At this point, we have not heard anything from Teva. At this point, we have not notified. I think Teva is clearly trying to work to understand that they have or they have the ability to meet the new FDA requirement for a XIFAXAN generic, given the fact that we now know there is some significant difference with the different polymers associated with XIFAXAN product. In the meantime, the only thing I would add to your question is say, we continue to develop what we think is a more patient-friendly formulation for the existing and for new indications of XIFAXAN. So we're not sitting still. We are continuing to go forward. And I think as I've said publicly, we are very confident in our intellectual property that supports XIFAXAN to make this a durable franchise.
是的。也許我再補充一點Paul所說的。再次強調,我認為Paul完全正確。我認為Paul和團隊在處理公司債務方面做得非常出色。如你所知,我們所做的是把我們產生的所有現金,首先、最優先用來償還債務。第二,我們過去也檢視了非核心資產的處分。而我們已經能夠——出售並從這些非核心資產處分中取得38億美元的收益。我想正如我們公開說過的,從現在起我們可能會考慮一些非核心資產處分,但那只會是機會性操作。我們並不是要在這裡努力增加這類處分。因此,這也讓我們有機會把部分營運資金改善所釋放的資金用於償債。我想這些會是主要的面向;我只是補充Paul所說的,因為我認為他已經回答得很好。關於XIFAXAN以及相關情況的問題。提醒大家一下——就我們所知,截至目前只有1件申請案。那就是Actavis/Teva的申請。Sandoz曾有一個計畫在進行,但就我們所看到的一切,他們已經中止了該計畫。——你說得沒錯。有一個為期1年的停止令(stay)到4月30日,並且也有一個監管停止令延續到2019年7月28日。截至目前,我們沒有聽到Teva的任何消息。截至目前,我們也沒有收到任何通知。我認為Teva顯然正在努力釐清:鑑於我們現在知道與XIFAXAN產品相關的不同聚合物之間存在一些顯著差異,他們是否已經或是否有能力符合FDA對XIFAXAN學名藥的新要求。同時,對你的問題我唯一要補充的是:我們持續開發我們認為對病患更友善的劑型,用於現有以及XIFAXAN的新適應症。所以我們並沒有停下來。我們會持續向前推進。而且我想我也曾公開表示,我們對支撐XIFAXAN的智慧財產權非常有信心,能讓這成為一個具持久性的產品系列(franchise)。
Operator
Operator
Your next question comes from the line of Umer Raffat with Evercore ISI.
下一個問題來自Evercore ISI的Umer Raffat。
Umer Raffat - Senior MD & Fundamental Research Analyst
Umer Raffat - Senior MD & Fundamental Research Analyst
Paul, maybe let me ask it more directly. Is there realistic possibility you may tap capital markets? Or maybe said another way, is there certain share price you need to see for you to pull the trigger? And I have a follow-up.
Paul,也許我更直接地問。你們是否有實際可能會進入資本市場籌資?或者換個說法,你們需要看到某個股價水準才會扣下扳機嗎?我還有一個追問。
Joseph C. Papa - Chairman of the Board and CEO
Joseph C. Papa - Chairman of the Board and CEO
Yes. Obviously, we never comment on what are plans might be with respect to raising equity capital. We started the question by saying, will you tap the capital markets? And I think, we tapped the capital markets multiple times, i.e. in 2017, but that being the term loan market, the secured note market and the unsecured note market. We will continue to evaluate opportunities to address our cap structure. I think the important thing here is, we stress it over and over again, the work that we completed in 2017, which is by no means over, not done. Enabled us to -- gave us the runway where I think everybody should be able to have a visual about how we work our way through what is and was a challenging debt stack. And then the last thing, I say it every time, equity has to be on the table, but I don't sit here today thinking that's something that's urgent. Again, please, the reason we put it into our script is, last thing we want is we file a shelf and somebody says, "Oh, look at this." It's like, this is just good corporate practice. If you sat in my seat, you would file a shelf.
是的。顯然,我們從不評論就籌措股權資本而言我們可能有哪些計畫。你一開始的問題是:你們會進入資本市場嗎?而我想,我們已經多次進入資本市場,也就是——在2017年,但那是指定期貸款市場、擔保票據市場以及無擔保票據市場。我們將持續評估改善我們資本結構的機會。我認為這裡重要的是,我們一再強調,我們在2017年完成的工作——這絕對還沒結束,還沒做完——讓我們——給了我們跑道,使我認為大家都應該能清楚看到我們如何逐步處理這個過去與現在都具挑戰性的債務結構。最後一點,我每次都會說:股權必須列入選項,但我今天坐在這裡並不認為那是急迫需要做的事。再次強調,請理解我們把它寫進講稿的原因是:我們最不希望的是我們提交了擱置式註冊,然後有人說:「喔,看這個。」就像——這只是良好的公司作法。如果你坐在我的位置,你也會提交擱置式註冊。
Umer Raffat - Senior MD & Fundamental Research Analyst
Umer Raffat - Senior MD & Fundamental Research Analyst
Got it, got it. And my follow-up, Paul, if I may, is, I think one of the themes throughout 2017 has been -- and maybe this is also for Joe. The theme in 2017 has been that you have a certain guidance in place, which assumes most of the LOE impact and the LOE impact is not as pronounced as what's guided and that results in beats. So my question is this. You have a similar phenomenon going on in '18, but there's something else going on as well. You're guiding to your base business, growing revenues at a certain 3% to 5%, but then the incremental EBITDA margin on that base revenue growth is only 15% to 40%. It's not the 90% EBIDTA hit you get on LOEs. So my point is, are you being conservative when you say LOEs get a 90% hit, whereas incremental revenues on base business are only at an incremental margin of 15% to 40% while SG&A will be flat year-over-year?
了解,了解。我接著追問一下,Paul,如果可以的話,我想2017年貫穿始終的一個主題是——也許這也適用於Joe。2017年的主題是,你們給出了一套指引,該指引假設了大部分LOE的影響,但實際上LOE的影響沒有指引所暗示的那麼明顯,因而帶來超預期。所以我的問題是這個。你們在2018年也有類似的現象,但同時還有另一件事。你們對核心業務給出的指引是營收以約3%到5%的速度成長,但在這部分核心營收成長之上,增量EBITDA利潤率只有15%到40%。這不像LOE那樣會帶來90%的EBITDA衝擊。所以我的重點是:你們說LOE會有90%的衝擊是否偏保守?而核心業務的增量營收卻只有15%到40%的增量利潤率,同時SG&A又將同比持平?
Paul S. Herendeen - EVP of Finance & CFO
Paul S. Herendeen - EVP of Finance & CFO
Yes, Umer, thank you for the question. Because it focuses right in on something that I tried to hit multiple times in my prepared remarks. You're absolutely correct is that the change in the adjusted EBITDA is not as pronounced as the change in what we expect in our base business. And the primary reason for that as we continue to invest behind our businesses in order to get the best long-term result and the things that I called out is, as Joe said, we're increasing the size of our derm sales force. We are continuing to use media, TV ads to support our consumer -- our U.S. B + L consumer business. We are continuing to engage in incremental promotional activities to drive our global lens business. We are intending to invest greater than 15% more in 2018 versus '17 in our R&D efforts. So you're not seeing any leverage on adjusted EBITDA relative to what you're seeing as growth in that base business, and that's kind of why I pointed to those things. I'll say it, our goal is not to maximize adjusted EBITDA in 2018, it's to ensure that we get each and every one of our core businesses stabilized and invested behind, so that we get the best long-term result. Quickly with respect to the LOE assets. The challenge here has always been that these are date uncertain. And when you have things that are date uncertain, one is, I feel, we feel as a company compelled to provide as much transparency as we can to the market. I daresay we're as good at it as anybody. Just now we've got the class of 2017 LOEs and class of 2018 LOEs. Each and everyone of you can make your own determination about what you think that trajectory will look like. But the point for me is, that's a bucket of revenue that you'd need to think about in the near-term, whether it's hitting in '18, whether it's hitting in '19, whether it's Q2 of '18, or Q4 or '18, you need to be thinking about it and you need to come to a point of view. We have taken what we believe is a good point of view by taking into consideration the things that can happen to us at the revenue line based on LOEs in 2018, the '17, and we've shared that with people. If people have a different view, that's what makes markets.
是的,Umer,謝謝你的提問。因為這個問題正好聚焦在我在事先準備的發言中多次試圖強調的一點。你完全正確:調整後EBITDA的變化幅度,沒有我們預期核心業務變化的幅度那麼明顯。其主要原因是,我們持續在各項業務上加大投資,以取得最佳的長期成果;我點到的幾點是——如Joe所說,我們正在擴大皮膚科銷售團隊的規模。我們持續使用媒體、電視廣告來支持我們的消費者——我們美國的B + L消費者業務。我們也持續投入額外的促銷活動,以推動我們的全球隱形眼鏡業務。我們計畫在2018年的研發投入相較於2017年增加超過15%。因此,你不會看到調整後EBITDA相對於核心業務成長出現槓桿效應,這也是我指出那些事項的原因。我直說,我們2018年的目標不是把調整後EBITDA最大化,而是確保我們每一項核心業務都能穩定下來並獲得投資支持,以取得最佳的長期成果。快速談一下LOE資產。這裡的挑戰一直在於:這些日期是不確定的。當你面對日期不確定的事項時,我覺得、我們作為公司覺得有責任向市場提供盡可能多的透明度。我敢說我們在這方面不比任何人差。目前我們有2017年那一批LOE,以及2018年那一批LOE。你們每一位都可以自行判斷你們認為那條軌跡會長什麼樣子。但對我而言重點是:這是一個你在短期內必須納入考量的營收桶——不論它是在2018年發生、2019年發生、是在2018年第二季,或是2018年第四季,你都需要把它納入思考並形成自己的觀點。我們在考量2018年LOE(包含2017年那批)可能對營收端造成的影響後,採取了我們認為合理的觀點,並已與大家分享。如果其他人有不同看法,這正是市場之所以存在的原因。
Joseph C. Papa - Chairman of the Board and CEO
Joseph C. Papa - Chairman of the Board and CEO
And I think pointing out to the specific products that Paul talked about, Lotemax, CUPRIMINE, APRISO and UCERIS, all not date certain. And that's the -- we tried to put our numbers forward and realizing that there is no specific date and when they will lose exclusivity, we simply are being prepared for that. If they do not lose exclusivity, obviously there is an upside. But we wanted to put forward the dates so that people have them as we -- how we are thinking about them.
我想也要指出Paul提到的具體產品:Lotemax、CUPRIMINE、APRISO和UCERIS,這些都不是日期確定的。而這就是——我們試著提出我們的數字,同時也意識到它們何時失去獨占性並沒有特定日期,所以我們只是為此做好準備。如果它們沒有失去獨占性,顯然就會有上行空間。但我們希望把這些日期提出來,讓大家掌握,因為這就是我們——我們如何看待它們的方式。
Operator
Operator
Your next question comes from the line of David Risinger of Morgan Stanley.
下一個問題來自Morgan Stanley的David Risinger。
David Reed Risinger - MD in Equity Research and United States Pharmaceuticals Analyst
David Reed Risinger - MD in Equity Research and United States Pharmaceuticals Analyst
So I just wanted to ask about cash flow and expectations for year-end debt. And so Paul, could you please discuss your expectations for cash flow in 2018 in some more detail, including operating cash flow and free cash flow? And what that would imply for year-end debt in 2018 relative to 2017?
我想問一下現金流以及年末負債的預期。Paul,你能否更詳細地談談你們對2018年現金流的預期,包括營運現金流與自由現金流?以及這對2018年年末負債相較於2017年意味著什麼?
Paul S. Herendeen - EVP of Finance & CFO
Paul S. Herendeen - EVP of Finance & CFO
Sure. Thanks for the question, David, and we look forward to seeing you later today. We don't guide to cash flow. But I will say a couple things -- repeat a couple things we said during the course of 2017 and then put 2018 in context. We generally said that a kind of middle of the road cash flow number per quarter, operating cash flow was about $500 million. And then it ended up that -- for the year, we ended up generating better than that, about $2.2 billion to $2.3 billion of cash flow from operations in 2017. That is in part due to some movements in accruals and settle ups and such things. But that $500 million per quarter number was a half decent estimate. Now not linear, just like everything, not linear. Thinking ahead to 2018, you have a reduced revenue and profit base and therefore, the $500 million needs to be adjusted based on your view of profitability in 2018. And I daresay, obviously, it's not $500 million, it is a lesser number than that due to divested assets, due to the continued runoff of the LOE bucket and the contraction of the dermatology business. Now that said, I expect that we will continue to produce cash flow in the neighborhood of the low $400 millions per quarter, and then we use that to invest back in the business. And by the way, that's cash flow from operations, so of course, you go to cover CapEx and all of our other cash costs and investments that we might make over the course of the year. We can continue to reduce debt through cash flow. I think you've seen some recent things. Earlier this year, we paid off another couple hundred million dollars. We had a press release actually this morning. We paid off another $71 million just using cash that was available. We will continue to have that ability as we go forward in 2018, and frankly, beyond. Again, this comes back to -- it always comes back to tax. We generate a significant or convert a significant proportion of our earnings into cash. And we will use that cash to reduce debt. We are focused, very focused on improving our working capital efficiency and to an extent that we improve our working capital efficiency, we'll use that cash as a priority to reduce our debt. I'm not sure that answered your question, but I think it gave you a direction.
當然。謝謝你的提問,David,我們也期待今天晚些時候見到你。我們不對現金流提供指引。但我會說幾點——重申幾點我們在2017年期間說過的內容,並把2018年放在脈絡中來看。我們一般說,每季一個相對中性的現金流數字,營運現金流大約是5億美元。而最終——就全年而言,我們2017年實際產生的營運現金流優於此,大約是22億到23億美元。這部分原因來自一些應計項目的變動、結算調整等因素。但每季5億美元這個數字算是相當不錯的估計。當然不是線性的,就像所有事情一樣,不是線性的。展望2018年,你的營收與利潤基礎會縮小,因此5億美元需要根據你對2018年獲利能力的看法進行調整。我敢說,顯然不會是5億美元;由於已剝離的資產、LOE那個營收桶持續流失,以及皮膚科業務的收縮,這個數字會更低。不過即便如此,我預期我們仍將持續產生每季約4億出頭美元的現金流,然後我們會用它再投資於業務。順帶一提,這是營運現金流,所以當然還要用來支付資本支出以及我們在一年中可能發生的其他現金成本與投資。我們可以透過現金流持續降低負債。我想你們也看到一些近期動作。今年稍早,我們又償還了另外幾億美元。我們其實今天早上也發了一則新聞稿。我們用可用現金又償還了7,100萬美元。在2018年往後推進時,坦白說,甚至更往後,我們都會持續具備這樣的能力。再次強調,這又回到——總是回到稅務。我們能把相當大比例的盈餘轉化為現金。而我們會用這些現金來降低負債。我們非常、非常專注於提升營運資金效率;在我們提升營運資金效率的程度上,我們會把釋放出的現金優先用於降低負債。我不確定這是否回答了你的問題,但我想至少給了你一個方向。
Operator
Operator
Your next question comes from the line of Annabel Samimy with Stifel.
您的下一個問題來自 Stifel 的 Annabel Samimy 專線。
Andrew Jay Finkelstein - Research Analyst
Andrew Jay Finkelstein - Research Analyst
This is Andrew in for Annabel. So any thoughts of go-forward margin impact of new launches both for gross and operating margin expectations as the product base turns over and new launch? Do you have any medium or long-term profitability targets? And also are the new dermatology launches you announced in your numbers?
我是 Andrew,代 Annabel 發問。那麼,隨著產品組合汰換並推出新產品,您對新上市產品對未來毛利率與營業利益率預期的影響有何看法?您是否有任何中期或長期的獲利目標?另外,您先前宣布的新皮膚科產品上市是否已反映在您目前的數字中?
Joseph C. Papa - Chairman of the Board and CEO
Joseph C. Papa - Chairman of the Board and CEO
Yes. So I'll start with this one. On the point of view of what you're saying is that we are going to invest in launching these new products, especially as we referred to the significant 7 as they get approved. There will be some investment there. But probably the best way to say is, just if you think about what we're saying about how we're thinking about EBIDTA and the leverage we see in the P&L. So yes, we do think there will be leverage in the P&L as you move from the revenue growth numbers to the operating line. I think it's important to say that the individual products that we're talking about will get incremental sales, marketing and promotional activities behind them. But we also think that the gross-to-nets for these products will be better than the overall Valeant as they represent new innovation in the marketplace. So probably that's all I can really say in terms of how we're thinking about in terms of -- yes, we will launch these new products. Yes, we think there is new innovation here. Yes, we believe the gross-to-nets will be better than historical Valeant products. And I think the only final comment is that as you think about the growth, especially in the dermatology, that growth is going to come with what we think is some improved leverage in the P&L.
是的。我先回答這題。就您提到的觀點而言,我們將會投資於這些新產品的上市,特別是我們提到的「重要 7 項」在獲批後的推進。這方面會有一些投入。但或許最好的說法是:如果您回想我們對 EBIDTA 的看法,以及我們在損益表中看到的營運槓桿。所以是的,我們確實認為,當您從營收成長數字往下走到營運線時,損益表會出現槓桿效應。我認為重要的是,我們所談到的個別產品,背後都會增加額外的銷售、行銷與推廣活動。但我們也認為,這些產品的 gross-to-nets 會優於 Valeant 整體水準,因為它們代表市場上的新創新。所以就我們如何思考而言,我大概只能說到這裡——是的,我們會推出這些新產品。是的,我們認為這裡有新的創新。是的,我們相信 gross-to-nets 會優於 Valeant 過去的產品。最後我想補充的是,當您思考成長、尤其是皮膚科的成長時,這個成長將伴隨我們認為在損益表上有所改善的槓桿。
Paul S. Herendeen - EVP of Finance & CFO
Paul S. Herendeen - EVP of Finance & CFO
Yes, Andrew, it's Paul. I want to -- I just want to follow on, because consistent with what we talked about in our prepared remarks and we have continued to talk about here, I think we -- thinking about margin, if you think about operating margin in '18, the '17, you look at you're going to expect the contraction. I mean, Umer brought up this point about the base business growing at one rate and the adjusted EBIDTA growing at a slower rate. It's -- we are going to see a decline in that margin as that tees us up for, as I said, better long-term performance. Our longer-term guidance implies that we will get leverage on our OpEx over the course of the period from '19 through '21. And I can tell you, I firmly believe that it's timing of supporting launches. I went through the list in my prepared remarks. If I missed one, I'll try and come back to it. But SILIQ, LUMIFY, VYZULTA coming up, DUOBRII, JEMDEL, contact lens, et cetera, et cetera, you invest behind those launches including not just in promotional campaigns but, as Joe said, the increase in the size of sales force in dermatology. That has a short-term impact on your margin and a beneficial impact on your long-term revenue and profit growth trajectories.
是的,Andrew,我是 Paul。我想——我只是想接著補充,因為這與我們在事先準備的發言中所談到、以及我們在這裡持續談到的內容一致。我認為我們——在思考利潤率時,如果您看 2018 年相對於 2017 年的營業利益率,您會預期它會收縮。我的意思是,Umer 提到這點:基礎業務以某個速度成長,而調整後 EBIDTA 以較慢的速度成長。也就是說——我們會看到該利潤率下降,這是為了讓我們如我所說,為更好的長期表現做好準備。我們較長期的指引意味著,在 2019 年到 2021 年這段期間,我們將在 OpEx 上取得槓桿效益。我可以告訴您,我堅信這是支援產品上市時點的問題。我在準備好的發言中列過清單。如果我漏了某個,我會試著再補回來。但像 SILIQ、LUMIFY、即將推出的 VYZULTA、DUOBRII、JEMDEL、隱形眼鏡等等等等,您會在這些上市上投入資源,不僅是推廣活動,還包括如 Joe 所說,擴大皮膚科銷售團隊規模。這會在短期內對利潤率造成影響,但會對長期營收與獲利成長軌跡帶來正面效益。
Operator
Operator
Your next question comes from the line of Louise Chen with Cantor.
您的下一個問題來自 Cantor 的 Louise Chen 專線。
Louise Alesandra Chen - Senior Research Analyst & MD
Louise Alesandra Chen - Senior Research Analyst & MD
I had a few here. So first question I had was that you talk about this turnround of a lifetime. But I think it's not really being reflected in your valuation. So just curious what you think the Street might be missing here? Second question I have is, following up on another question earlier, if you could provide more color on your ending debt balance and the leverage ratio for the year. And then last question was seems like derm is still a very important part of your business. Just curious if you have any interest in aesthetics for dermatology or really your focus remains on medical dermatology?
我這裡有幾個問題。第一個問題是,您談到這是「一生一次的轉型」。但我認為這似乎沒有反映在你們的估值上。所以想請教您覺得市場可能忽略了什麼?第二個問題是,延續先前另一個問題,您是否能更詳細說明今年期末的債務餘額以及槓桿比率?最後一個問題是,皮膚科看起來仍是你們業務非常重要的一部分。想請教你們對皮膚科醫美(aesthetics)是否有興趣,還是重點仍放在醫療皮膚科?
Joseph C. Papa - Chairman of the Board and CEO
Joseph C. Papa - Chairman of the Board and CEO
Right, I will start with the commentary. Yes, I do absolutely believe that the turnaround of a lifetime is true. I do think it takes some time, and we have to demonstrate the performance. And what we're trying to do right now is show that in more than 75% of the business, Bausch + Lomb/International plus the Salix business, if you combine those that, we're seeing mid-single-digit growth rate. We think that's obviously important. At the same time, we try to be as transparent as possible that we do have some loss of exclusivity, some divestitures that we made, that because of those we have a 2018 as what we're -- Paul referred to, I believe, is a trough year. I'll probably go one step further and say that the -- based on the seasonality of any year, we probably are in the trough quarter if you think about Q1 being the lower -- the lowest percentage of the performance. Having said that, where we're going from there is always going to be about launching these new products. We're launching the new products as we think they represent the significant turnaround for dermatology, first and foremost, but also as we referred to the significant 7 help us in the Bausch & Lomb business, the Salix business and of course, the dermatology. So that to me is the reason why we're excited about the future and where it goes. Paul, why don't you talk about the ending debt balance?
好的,我先回應評論部分。是的,我完全相信「一生一次的轉型」這句話是真的。我確實認為這需要一些時間,而且我們必須用表現來證明。我們現在要做的是展示:在超過 75% 的業務中,也就是 Bausch + Lomb/International 加上 Salix 業務,如果把它們合在一起,我們看到的是中個位數的成長率。我們認為這顯然很重要。同時,我們也盡可能透明地說明:我們確實面臨一些專利到期(失去獨占性)、以及我們做過的一些資產剝離;因為這些因素,2018 年如 Paul 所提到的,我相信,是一個谷底年。我可能再進一步說,基於每年的季節性,如果您認為第一季通常是——表現占比最低的一季,那我們現在可能正處於谷底季度。話雖如此,我們接下來要往哪裡走,永遠都會圍繞著推出這些新產品。我們推出新產品,是因為我們認為它們代表皮膚科最重要、最優先的重大轉型;同時,如我們提到的「重要 7 項」也將幫助我們的 Bausch & Lomb 業務、Salix 業務,當然也包括皮膚科。所以對我而言,這就是我們對未來及其走向感到興奮的原因。Paul,你來談談期末債務餘額吧?
Paul S. Herendeen - EVP of Finance & CFO
Paul S. Herendeen - EVP of Finance & CFO
Yes. We're not going to guide to. I mean, it's kind of a different way of coming at the cash flow and how you are going to use it to reduce debt. We're not going to guide to an ending debt balance. Sorry, Louise.
好的。我們不會提供這方面的指引。我的意思是,這是一種不同的角度來看現金流,以及你將如何運用它來降低負債。我們不會提供期末債務餘額的指引。抱歉,Louise。
Joseph C. Papa - Chairman of the Board and CEO
Joseph C. Papa - Chairman of the Board and CEO
And then the last part was the derm interest in aesthetics. We have a great business in Solta. As we look at Solta, there is an opportunity we believe to leverage our Solta business, combine it with what we're doing with our medical dermatology and get the value for the total dermatology patients and physicians. So yes, we do think there's value in the medical dermatology. We're excited about some of the new innovation that we have in Thermage and Fraxel. All those products we think will help us for the future.
至於最後一部分,關於皮膚科對醫美的興趣。我們在 Solta 有一個很棒的業務。在看 Solta 時,我們相信有機會發揮 Solta 業務的槓桿,將其與我們在醫療皮膚科所做的事情結合,為整體皮膚科患者與醫師創造價值。所以是的,我們確實認為醫療皮膚科有價值。我們也對 Thermage 和 Fraxel 的一些新創新感到興奮。我們認為這些產品都將在未來幫助我們。
Operator
Operator
Your next question comes from Chris Schott of with JPMorgan.
您的下一個問題來自 JPMorgan 的 Chris Schott。
Christopher Z. Neyor - Analyst
Christopher Z. Neyor - Analyst
This is Chris Neyor on for Chris Schott. My first question's on the Branded Rx pricing environment, just generally. Last year, you had a reset in the dermatology business. When we think about your pricing and access through GI in dermatology business in the U.S. this year, should we think about a more normalized price environment? Or are there any headwinds that you would -- we should be keeping in mind? Second question is on just the dermatology launches you guys have coming up in the second half of 2018. Should we think about these as more gradual? Or should we think that you could potentially have a more rapid launch process?
我是 Chris Neyor,代 Chris Schott 發問。我的第一個問題是關於品牌處方藥(Branded Rx)的定價環境,整體而言。去年你們的皮膚科業務進行了一次重置。當我們思考今年你們在美國皮膚科業務中,透過 GI(腸胃科)在定價與准入方面的情況時,我們是否應該把它視為較為正常化的價格環境?或者是否有任何逆風是我們應該留意的?第二個問題是關於你們在 2018 年下半年即將推出的皮膚科產品。我們應該把這些上市視為較為漸進的推進嗎?或者我們應該認為你們可能會有更快速的上市節奏?
Joseph C. Papa - Chairman of the Board and CEO
Joseph C. Papa - Chairman of the Board and CEO
Sure. Let me start on the brand Rx pricing environment. We think it is a market where with any -- whatever price increase we take, we will realize approximately half of that in terms of net realized price. So we, as you may know, have tried very hard to stay within our branded prescription product pricing market within the single-digit range. And since we've put together our patient access and pricing committee, we've been able to do that and keep pricing at a single-digit range. I would say that, if I just use a number just for the sake for argument on any product that if we take an 8% price increase or a 6% price increase, we expect we would realize approximately half of that in terms of the value, in terms of the net realized price, the rest would be absorbed by the channel. On the question of where we see that gross-to-net, I think our gross-to-net we think is going to be relatively stable. The big change in gross-to net usually always occur if there is significant new competitor showing up in the category. Otherwise, it's a relatively stable pricing. There is a push-pull on that, of course, from our channel dynamics. On the question on the derm launches. We think that each one of them is a different category by itself. The SILIQ product we expect it to be slower launch. And I made that comment in my remarks based on the labeling. But based on the fact that it is a IL-17 receptor blocker, we believe that, that receptor blockade is going to give good patient response over the long term. So that's clearly one that we do think over the long-term, we're delighted to see that 90% of the patients are staying on therapy. The other products in the derm category, we do believe are going to be a faster onset or faster ramp than the SILIQ product as we look -- go forward with the future. We're already very excited about some of the initial prescription data we're seeing on the Retin-A Micro 0.06%. That's ramping up very nicely in a very quick timetable already. Operator, I think, I have time for one more question.
好的。我先從品牌處方藥(Rx)的定價環境談起。我們認為這是一個市場:無論我們採取任何——不管我們做出什麼樣的漲價,我們在淨實現價格(net realized price)上大約只能實現其中的一半。因此,如你所知,我們一直非常努力,讓我們的品牌處方產品定價漲幅維持在個位數區間。自從我們成立病患可近性與定價委員會以來,我們就能做到這一點,並將定價維持在個位數範圍。我想說,僅為了便於說明,若以任何產品為例,假設我們提價8%或提價6%,我們預期在價值上、在淨實現價格上大約只能實現其中的一半,其餘會被通路吸收。至於你問到我們如何看待毛到淨(gross-to-net),我認為我們的毛到淨應該會相對穩定。毛到淨最大的變化通常幾乎總是發生在某一品類出現重要的新競爭者時。否則,定價相對穩定。當然,這其中也會受到通路動態的拉鋸影響。再談皮膚科產品上市的問題。我們認為每一個產品本身都屬於不同的品類。我們預期SILIQ產品的上市會較為緩慢。我在發言中之所以這麼說,是基於其標示(labeling)。但鑑於它是IL-17受體阻斷劑,我們相信這種受體阻斷將在長期帶來良好的病患反應。因此,這顯然是我們認為長期表現會很好的產品;我們也很高興看到有90%的病患持續接受治療。至於皮膚科品類中的其他產品,我們相信相較於SILIQ,未來它們的起效或放量速度會更快。我們已經對Retin-A Micro 0.06%看到的一些初期處方數據感到非常振奮。它在非常短的時間表內就已經放量得很不錯。接線員,我想我還有時間再回答一個問題。
Operator
Operator
Your next question comes from Gary Nachman with BMO Capital Markets.
下一個問題來自BMO Capital Markets的Gary Nachman。
Gary Jay Nachman - Analyst
Gary Jay Nachman - Analyst
Back on the 2018 EBIDTA guidance, I know you want to spend more this year. But how much flexibility do you have with expenses? So if there are some headwinds on the top line during the year that you'd be able to hold back spending. And where would that potentially come from? And then how aggressive are you looking at additional divestitures? And are you actually at a point where you could consider bringing in some new assets? And what areas might you do that?
回到2018年EBIDTA指引,我知道你們今年想增加支出。但在費用方面你們有多大的彈性?也就是說,如果今年營收端出現一些逆風,你們是否能夠暫緩支出。而這可能會從哪些項目中來?另外,你們對進一步資產剝離(divestitures)的態度有多積極?你們是否已經到了可以考慮引入一些新資產的階段?以及可能會在哪些領域這麼做?
Joseph C. Papa - Chairman of the Board and CEO
Joseph C. Papa - Chairman of the Board and CEO
Sure. I'll start in EBITDA guidance comment and say, when we crafted this guidance, we tried to be aware of all the issues that could potentially affect it, like the loss of exclusivity, like the new products, like our investment that Paul mentioned. Our view is it's the correct number for what we're trying to do with our plans right now. But with any plan, you always have the ability to manage it during the course of the year. On the second part of that question was about divestitures. We've been very successful. We sold -- realized proceeds of $3.8 billion over the last 18 months. We believe that those proceeds are coming in at an approximate EBITDA multiple on average of approximately 10x, so we -- with the milestone payments. So we feel we've realized what we needed to do. And we, fortunately, have done it with all non --what I would refer to as noncore asset sales. So for that reason we've been able to continue to keep our core, our core being where we want to be in the Bausch + Lomb eye care business, the dermatology business and the Salix GI business are the primary core by which we want to build around. I think on where we'd go with potential new assets here, you heard some of that today when we talked about the Kaken asset that we acquired for new example -- new opportunity to treat topically the product category for psoriasis. That's -- we think is an exciting product for us for the future. You've heard us talk about in the past when we licensed in the PLENVU product. The PLENVU product is a product that we're awaiting FDA approval. We have a May 18 PDUFA date. That's another example of what's building out in our GI category. So what you expect to hear from us as we look to the future is that we'll continue to make investments in areas where we want to remain in our core, our dermatology, eye care and our GI business.
好的。我先談EBITDA指引並說明:在制定這份指引時,我們試圖把所有可能影響它的議題都納入考量,例如專利/獨家權到期(loss of exclusivity)、新產品,以及Paul提到的我們的投資。我們的看法是,就我們目前計畫要做的事情而言,這是一個正確的數字。但任何計畫在一年進行的過程中,你總是有能力去管理與調整。你問題的第二部分是關於資產剝離。我們做得非常成功。過去18個月我們出售資產——累計實現了38億美元的處分收入。我們認為這些收入平均約以10倍的EBITDA倍數成交——並且包含里程碑付款。因此我們覺得已經實現了我們需要完成的目標。而且幸運的是,我們所做的都是我所稱的非核心資產出售。因此,我們得以持續保留核心業務;我們的核心是我們希望聚焦並圍繞其發展的領域:Bausch + Lomb眼科護理業務、皮膚科業務,以及Salix腸胃(GI)業務,這些是我們要建立的主要核心。至於未來可能引入哪些新資產,你今天也聽到一些例子:我們談到我們收購的Kaken資產,作為一個新的例子——一個以外用方式治療乾癬產品類別的新機會。我們認為這對我們未來而言是令人興奮的產品。你們也聽過我們過去談到我們授權引進(licensed in)的PLENVU產品。PLENVU目前正在等待FDA核准。我們的PDUFA日期是5月18日。這是我們在GI品類持續擴充的另一個例子。因此,展望未來,你們可以預期我們會持續在我們希望維持核心地位的領域進行投資,也就是皮膚科、眼科護理以及GI業務。
Arthur J. Shannon - Senior VP and Head of IR & Communications
Arthur J. Shannon - Senior VP and Head of IR & Communications
That concludes what we wanted to say today. Everyone, thank you very much for joining us. We look forward to meeting many of you over the next few weeks and months ahead. Please let us know if there are any questions, we'll be happy to try to provide some additional information. Thank you, everyone, for joining us. Have a great day.
以上就是我們今天想說的內容。各位,非常感謝你們參與。我們期待在接下來幾週與幾個月內與各位中的許多人見面。如果有任何問題,請告訴我們,我們很樂意嘗試提供更多資訊。謝謝大家今天的參與。祝各位有美好的一天。
Operator
Operator
This concludes today's conference call. You may now disconnect.
今天的電話會議到此結束。您現在可以掛線。